StumpeKO. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. Clin Ther. 2004;26(suppl A):A33–A37.
2.
Rubio-TapiaAHermanMLLudvigssonJF, et al.Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc. 2012;87(8):732–738.
3.
NaranjoCABustoUSellersEM, et al.A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239–245.
4.
MariettaEVCarteeARishiA, et al.Drug-induced enteropathy. Dig Dis. 2015;33(2):215–220.
5.
MartheyLCadiotGSeksikP, et al.Olmesartan-associated enteropathy: results of a national survey. Aliment Pharmacol Ther. 2014;40(9):1103–1109.
6.
BurbureNLebwohlBArguelles-GrandeC, et al.Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Hum Pathol. 2016;50:127–134.
7.
DowneyLHoutenRMurchS, et al.Guideline Development Group. Recognition, assessment, and management of coeliac disease: summary of updated NICE guidance. BMJ.2015;351:h4513.
8.
US Preventive Services Task Force;Bibbins-DomingoKGrossmanDC, et al.Screening for Celiac Disease: US Preventive Services Task Force Recommendation Statement. JAMA. 2017;317(12):1252–1257.
9.
KamalAFainCParkA, et al.Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue-like enteropathy: a systematic review. Gastroenterol Rep (Oxf). 2019;7(3):162–167.
10.
Marco-MarquésASanahuja-MartinezABosca-WattsMM, et al.Could HLA-DQ suggest why some patients have olmesartan-related diarrhea and others don’t?Am J Gastroenterol. 2015;110(10):1507–1508.
